Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study
机构:[1]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Phase I Clin Trial Ctr, Guangzhou, Peoples R China中山大学附属第二医院[2]Zhengzhou Univ, Affiliated Canc Hosp, Henan Breast Canc Ctr, Dept Breast Dis, Zhengzhou, Peoples R China河南省肿瘤医院[3]Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[4]Tianjin Med Univ Canc Inst & Hosp, Breast Med Oncol, Tianjin, Peoples R China[5]Huazhong Univ Sci & Technol, Dept Breast Surg, Hubei Canc Hosp,Wuhan Clin Res Ctr Breast Canc, Tongji Med Coll,Hubei Prov Clin Res Ctr Breast Can, Wuhan, Peoples R China[6]Nanjing Med Univ, Affiliated Hosp 1, Clin Res, Nanjing, Peoples R China江苏省人民医院[7]Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Peoples R China江苏省人民医院[8]Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea[9]Macquarie Univ, Macquarie Med Sch, Sydney, Australia[10]Hunan Canc Hosp, Dept Urinary Surg, Changsha, Peoples R China[11]Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Coll Med, Hematol & Med Oncol, Seongnam, South Korea[12]Cent South Univ, Xiangya Hosp, Dept Breast Surg, Natl Agency Clin Trial Med, Changsha, Peoples R China[13]Wuhan Univ, Zhongnan Hosp, Radiat & Med Oncol, Wuhan 430071, Peoples R China[14]Alfred Hlth, Med Oncol, Melbourne, Vic, Australia[15]Monash Univ, Cent Clin Sch, Melbourne, Australia[16]Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China[17]Montefiore Einstein Ctr Canc Care, Med Oncol, Bronx, NY USA[18]China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang, Peoples R China中国医科大学附属盛京医院中国医科大学盛京医院[19]Fujian Med Univ, Melanoma Urol Soft Tissue Tumor Internal Med, Canc Hosp, Fuzhou, Peoples R China[20]Seoul Natl Univ Hosp, Hematol & Oncol, Seoul 110744, South Korea[21]Chinese Acad Med Sci, Canc Hosp, Gynecol Oncol, Beijing, Peoples R China[22]Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Biliary & Pancreat Surg, Shanghai, Peoples R China[23]PASO Med, Hematol & Oncol, Melbourne, Vic, Australia[24]Mary Crowley Canc Res, Med Oncol, Dallas, TX USA[25]Sichuan Canc Hosp, Dept Breast Surg, Chengdu, Sichuan, Peoples R China外科中心乳腺外科中心四川省肿瘤医院[26]Southern Med Univ, Nanfang Hosp, Breast Ctr, Dept Gen Surg, Guangzhou, Peoples R China[27]Hubei Canc Hosp, Hepat Biliary Pancreat Surg, Wuhan, Peoples R China[28]China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China[29]Bengbu Med Coll, Affiliated Hosp 1, Surg Oncol, Bengbu, Peoples R China[30]Bengbu Med Coll, Affiliated Hosp 1, Phase 1 Clin Trial Lab, Bengbu, Peoples R China[31]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Surg, Guangzhou 510120, Peoples R China中山大学附属第二医院[32]Jiangsu Hengrui Pharmaceut Co Ltd, Oncol Clin Res & Dev, Shanghai, Peoples R China[33]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Tumor Ctr, Guangzhou, Peoples R China中山大学附属第二医院
第一作者机构:[1]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Phase I Clin Trial Ctr, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Yao H.,Yan M.,Tong Z.,et al.Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study[J].BREAST.2025,80:doi:10.1016/j.breast.2025.103912.
APA:
Yao, H.,Yan, M.,Tong, Z.,Wu, X.,Yin, Y....&Song, E..(2025).Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study.BREAST,80,
MLA:
Yao, H.,et al."Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study".BREAST 80.(2025)